TCI Wealth Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

TCI Wealth Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-331	Closed	-$10.7K	–	2357
2023 Q1	$10.7K	Buy	+331	New	+$10.3K	﹤0.01%	1054
2022 Q2	–	Sell	-267	Closed	-$5K	–	2562
2022 Q1	$5K	Hold	267	–	–	﹤0.01%	1623
2021 Q4	$4K	Buy	267 +118	+79%	+$1.97K	﹤0.01%	1936
2021 Q3	$4K	Hold	149	–	–	﹤0.01%	1853
2021 Q2	$4K	Buy	149 +4	+3%	+$115	﹤0.01%	1660
2021 Q1	$4K	Buy	+145	New	+$4.01K	﹤0.01%	1447

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCI Wealth Advisors's RVNC Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 331 shares — an estimated $10.7K sold.

TCI Wealth Advisors first reported a position in RVNC in Q1 2021 and held it in 6 quarters. The position peaked at $10.7K in Q1 2023. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

TCI Wealth Advisors reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 331 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $10.7K.
TCI Wealth Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2021 and held it in 6 quarters.
TCI Wealth Advisors's Revance Therapeutics, Inc. position peaked at $10.7K in Q1 2023.
215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.